Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia
Sponsor: Hiroshima University Hospital
Summary
This is Phase I/II Dose-Escalation Study to evaluate the tolerability, safety, efficacy and pharmacokinetics of PPMX-T003 in aggressive NK-cell leukemia.
Official title: Multicenter, Open-label, Dose-escalation Phase I/II Study to Evaluate the Tolerability, Safety, Efficacy and Pharmacokinetics of Repeated Continuous Intravenous PPMX-T003 in Patients With Aggressive NK Cell Leukaemia (ANKL) (Physician-initiated Clinical Trial)
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
7
Start Date
2023-09-21
Completion Date
2026-03-31
Last Updated
2025-04-30
Healthy Volunteers
No
Conditions
Interventions
PPMX-T003
The therapeutic agent is administered continuously intravenously
Locations (1)
Hiroshima University Hospital
Hiroshima, Hiroshima, Japan